Cordyceps Sunshine Biotech Holdings (RAJAF) Receivables (2021 - 2025)

Cordyceps Sunshine Biotech Holdings' Receivables history runs 4 years deep, the most recent figure standing at $5068.0 for Q4 2025.

• In Q4 2025, Receivables changed N/A year-over-year to $5068.0; the TTM figure through Dec 2025 stood at $5068.0 (changed N/A YoY), while the FY2025 annual figure was $5068.0, changed N/A from the prior year.
• Receivables was $5068.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, up from $2442.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $240573.0 in Q4 2021 to a low of $2442.0 in Q4 2023.
• Historically, Receivables has averaged $64396.2 across 4 years, with a median of $7285.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables tumbled 96.05% in 2022, then slumped 74.3% in 2023.
• A 4-year view of Receivables shows it stood at $240573.0 in 2021, then sank by 96.05% to $9502.0 in 2022, then plunged by 74.3% to $2442.0 in 2023, then soared by 107.53% to $5068.0 in 2025.
• The last three Receivables figures came in at $5068.0 (Q4 2025), $2442.0 (Q4 2023), and $9502.0 (Q4 2022), per Business Quant data.